Applied DNA Sciences, a company involved in PCR-based DNA technologies, appointed Beverly Wolgast, executive director of Quality and cGMP Programs. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the company's three business segments, including implementing an ISO 13485-based quality management system for the scalable cGMP manufacture of LineaDNA.
Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date
Applied DNA Submits Validation Package to New York State Department of Health for Approval of Pharmacogenomic (PGx) Assay
Applied DNA Announces New York State Award Valued at Up To $1.5 Million to Support Establishment of cGMP linearDNA™ Production Capacity on Long Island, New York
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development. The study, titled ‘A linear DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain elicits protective immunity in domestic cats,’ supports the further development of the Company’s LinearDNA™ platform for the large-scale enzymatic (PCR, polymerase chain reaction) production of prophylactic and therapeutic linearDNA™-based vaccines. An initial manuscript detailing the study’s findings was published in preprint form on bioRxiv in July 2022.